Clinical Study
An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients
Table 1
Patients’ characteristics and bone-marrow aspirates.
| | Variables | Total patients: |
| | Male gender (%) | 40 (56%) | | Age at bone-marrow aspiration (years) | | | First kidney transplantation (%) | 61 (85%) | | Diabetes mellitus (%) | 13 (18%) | | Serum-creatinine level (µmol/L) | | | eMDRD GFR (mL/min) | | | Immunosuppressive therapy | | | Induction therapy (%) | 57 (79%) | | RATG/anti-IL2R induction therapy (%) | 18 (25%)/39 (54%) | | RATG for induction or rejection therapy (%) | 22 (31%) | | Rituximab (%) | 13 (18%) | | Calcineurin inhibitors (%) | 63 (88%) | | Cyclosporine A/tacrolimus (%) | 51 (71%)/12 (17%) | | mTOR inhibitors (%) | 4 (5%) | | Belatacept (%) | 5 (7%) | | Mycophenolic acid (%) | 60 (83%) | | Steroids (%) | 72 (100%) | | History of acute rejection | | | Steroid-sensitive acute-rejection episodes (%) | 13 (18%) | | Steroid-resistant acute-rejection episodes (%) | 9 (12.5%) | | Antibody-mediated rejection episodes (%) | 10 (14%) | | History of viral replication | | | Positive BK viremia | 5 (7%) | | PVAN | 2 (3%) | | CMV replication | 17 (24%) |
|
|
RATG: rabbit anti-thymocyte globulins; anti-IL2R: anti-interleukin-2 receptors; mTOR: mammalian target of rapamycin; PVAN: polyomavirus-associated nephropathy; CMV: cytomegalovirus.
|
